keyword
MENU ▼
Read by QxMD icon Read
search

ctDNA

keyword
https://www.readbyqxmd.com/read/27912082/low-dimensional-compounds-containing-bioactive-ligands-part-viii-dna-interaction-antimicrobial-and-antitumor-activities-of-ionic-5-7-dihalo-8-quinolinolato-palladium-ii-complexes-with-k-and-cs-cations
#1
Veronika Farkasová, Sayed Ali Drweesh, Andrea Lüköová, Danica Sabolová, Ivana D Radojević, Ljiljana R Čomić, Sava M Vasić, Helena Paulíková, Stanislav Fečko, Tatiana Balašková, Mária Vilková, Ján Imrich, Ivan Potočňák
Starting from well-defined NH2(CH3)2[PdCl2(XQ)] complexes, coordination compounds of general formula Cat[PdCl2(XQ)] have been prepared by cationic exchange of NH2(CH3)2(+) and Cat cations, where XQ are biologically active halogen derivatives of quinolin-8-ol (5-chloro-7-iodo-quinolin-8-ol (CQ), 5,7-dibromo-quinolin-8-ol (dBrQ) and 5,7-dichloro-quinolin-8-ol (dClQ)) and Cat is K(+) or Cs(+). The cation exchange of all prepared complexes, K[PdCl2(CQ)] (1), K[PdCl2(dClQ)] (2), K[PdCl2(dBrQ)] (3), Cs[PdCl2(CQ)] (4), Cs[PdCl2(dClQ)] (5) and Cs[PdCl2(dBrQ)] (6) was approved using IR spectroscopy, their structures in DMSO solution were elucidated by one- and two-dimensional NMR experiments, whereas their stability in solution was verified by UV-VIS spectroscopy...
November 16, 2016: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/27899805/circulating-tumour-dna-analysis-demonstrates-spatial-mutational-heterogeneity-that-coincides-with-disease-relapse-in-myeloma
#2
S Mithraprabhu, T Khong, M Ramachandran, A Chow, D Klarica, L Mai, S Walsh, D Broemeling, A Marziali, M Wiggin, J Hocking, A Kalff, B Durie, A Spencer
Mutational characterisation in multiple myeloma (MM) currently relies on bone marrow (BM) biopsy, which fails to capture the putative spatial and genetic heterogeneity of this multi-focal disease. Analysis of plasma (PL)-derived circulating free tumour DNA (ctDNA) as an adjunct to BM biopsy, for mutational characterisation and tracking disease progression, was evaluated. Paired BM MM cell DNA and ctDNA from 33 relapsed [RR] and 15 newly diagnosed [ND] patients were analysed for KRAS, NRAS, BRAF and TP53 mutations using the OnTarget™ Mutation Detection (OMD) platform...
November 30, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27889670/selective-recognition-of-cis-trans-isomers-of-platinum-drugs-and-the-detection-of-triplex-dna-based-on-fluorescence-reversible-model-of-quantum-dots
#3
Xiaoling Xu, Fang Gao, Xincai Xiao, Yan Hu, Chaozhen Zhu, Dan Zhao
The identification of spatial structures of drugs and the researches on their interaction mechanism with DNA are always attractive to the researchers. However, their realization is lack of simple and fast method. This paper reports the establishment of multiple-functional detection platform based on the "turn off-on" model of ZnCdSe quantum dots. In this system, ZnCdSe quantum dots work as the fluorescent probe, platinum anti-cancer drugs as the quencher and triplex DNA as the trapping agent. The seemingly similar cisplatin and transplatin exhibited different fluorescent recovery behaviors due to their difference in structure, and thus realized the selective detection of cisplatin and transplatin with the reaction time set at 10min as well as the quantitation of cisplatin over the range of 2...
November 19, 2016: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/27865784/a-comparison-of-cell-free-dna-isolation-kits-isolation-and-quantification-of-cell-free-dna-in-plasma
#4
Laure Sorber, Karen Zwaenepoel, Vanessa Deschoolmeester, Geert Roeyen, Filip Lardon, Christian Rolfo, Patrick Pauwels
The analysis of cell-free DNA (cfDNA) as a sensitive biomarker for cancer diagnosis and monitoring has resulted in a need for efficient and standardized cfDNA isolation. In this study, we compared the isolation efficiency of the QIAamp circulating nucleic acid kit (QIA) with four other cfDNA isolation kits: the PME free-circulating DNA Extraction Kit (PME), the Maxwell RSC ccfDNA Plasma Kit (RSC), the EpiQuick Circulating Cell-Free DNA Isolation Kit (EQ), and two consecutive versions of the NEXTprep-Mag cfDNA Isolation Kit (NpMV1/2)...
November 17, 2016: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/27863505/a-genomic-case-study-of-desmoplastic-small-round-cell-tumor-comprehensive-analysis-reveals-insights-into-potential-therapeutic-targets-and-development-of-a-monitoring-tool-for-a-rare-and-aggressive-disease
#5
Elisa Napolitano Ferreira, Bruna Durães Figueiredo Barros, Jorge Estefano de Souza, Renan Valieris Almeida, Giovana Tardin Torrezan, Sheila Garcia, Ana Cristina Victorino Krepischi, Celso Abdon Lopes de Mello, Isabela Werneck da Cunha, Clóvis Antonio Lopes Pinto, Fernando Augusto Soares, Emmanuel Dias-Neto, Ademar Lopes, Sandro José de Souza, Dirce Maria Carraro
BACKGROUND: Genome-wide profiling of rare tumors is crucial for improvement of diagnosis, treatment, and, consequently, achieving better outcomes. Desmoplastic small round cell tumor (DSRCT) is a rare type of sarcoma arising from mesenchymal cells of abdominal peritoneum that usually develops in male adolescents and young adults. A specific translocation, t(11;22)(p13;q12), resulting in EWS and WT1 gene fusion is the only recurrent molecular hallmark and no other genetic factor has been associated to this aggressive tumor...
November 18, 2016: Human Genomics
https://www.readbyqxmd.com/read/27863403/enumeration-and-targeted-analysis-of-kras-braf-and-pik3ca-mutations-in-ctcs-captured-by-a-label-free-platform-comparison-to-ctdna-and-tissue-in-metastatic-colorectal-cancer
#6
Evelyn Kidess-Sigal, Haiyan E Liu, Melanie M Triboulet, James Che, Vishnu C Ramani, Brendan C Visser, George A Poultsides, Teri A Longacre, Andre Marziali, Valentina Vysotskaia, Matthew Wiggin, Kyra Heirich, Violet Hanft, Ulrich Keilholz, Ingeborg Tinhofer, Jeffrey A Norton, Mark Lee, Elodie Sollier-Christen, Stefanie S Jeffrey
Treatment of advanced colorectal cancer (CRC) requires multimodal therapeutic approaches and need for monitoring tumor plasticity. Liquid biopsy biomarkers, including CTCs and ctDNA, hold promise for evaluating treatment response in real-time and guiding therapeutic modifications. From 15 patients with advanced CRC undergoing liver metastasectomy with curative intent, we collected 41 blood samples at different time points before and after surgery for CTC isolation and quantification using label-free Vortex technology...
November 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27832189/performance-of-streck-cfdna-blood-collection-tubes-for-liquid-biopsy-testing
#7
Inga Medina Diaz, Annette Nocon, Daniel H Mehnert, Johannes Fredebohm, Frank Diehl, Frank Holtrup
OBJECTIVES: Making liquid biopsy testing widely available requires a concept to ship whole blood at ambient temperatures while retaining the integrity of the cell-free DNA (cfDNA) population and stability of blood cells to prevent dilution of circulating tumor DNA (ctDNA) with wild-type genomic DNA. The cell- and DNA-stabilizing properties of Streck Cell-Free DNA BCT blood collection tubes (cfDNA BCTs) were evaluated to determine if they can be utilized in combination with highly sensitive mutation detection technologies...
2016: PloS One
https://www.readbyqxmd.com/read/27831904/distinct-biological-subtypes-and-patterns-of-genome-evolution-in-lymphoma-revealed-by-circulating-tumor-dna
#8
Florian Scherer, David M Kurtz, Aaron M Newman, Henning Stehr, Alexander F M Craig, Mohammad Shahrokh Esfahani, Alexander F Lovejoy, Jacob J Chabon, Daniel M Klass, Chih Long Liu, Li Zhou, Cynthia Glover, Brendan C Visser, George A Poultsides, Ranjana H Advani, Lauren S Maeda, Neel K Gupta, Ronald Levy, Robert S Ohgami, Christian A Kunder, Maximilian Diehn, Ash A Alizadeh
Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains challenging. In addition, the biology underlying these differences is incompletely understood. We hypothesized that characterization of mutational heterogeneity and genomic evolution using circulating tumor DNA (ctDNA) profiling could reveal molecular determinants of adverse outcomes. To address this hypothesis, we applied cancer personalized profiling by deep sequencing (CAPP-Seq) analysis to tumor biopsies and cell-free DNA samples from 92 lymphoma patients and 24 healthy subjects...
November 9, 2016: Science Translational Medicine
https://www.readbyqxmd.com/read/27827317/the-effect-of-preservative-and-temperature-on-the-analysis-of-circulating-tumor-dna
#9
Sonya Parpart-Li, Bjarne Bartlett, Maria Popoli, Vilmos Adleff, Laura Tucker, Rebecca Steinberg, Andrew Georgiadis, Jillian Phallen, Julie R Brahmer, Nilofer A Azad, Ilene Browner, Daniel A Laheru, Victor E Velculescu, Mark Sausen, Luis A Diaz
PURPOSE: Analysis of genomic alterations in cell-free DNA (cfDNA) is evolving as an approach to detect, monitor and genotype malignancies. Methods to separate the liquid from the cellular fraction of whole blood for circulating tumor DNA (ctDNA) analyses have been largely unstudied although these may be a critical consideration for assay performance. EXPERIMENTAL DESIGN: To evaluate the influence of blood processing on cfDNA and ctDNA quality and yield, we compared the cfDNA levels in serum to those in plasma...
November 8, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27826535/usefulness-of-circulating-free-dna-for-monitoring-epidermal-growth-factor-receptor-mutations-in-advanced-non-small-cell-lung-cancer-patients-a-case-report
#10
Clara Mayo de Las Casas, Maria Gonzalez-Cao, Santiago Viteri Ramirez, Nuria Jordana Ariza, Ariadna Balada, Mónica Garzón, Cristina Teixidó, Niki Karachaliou, Daniela Morales-Espinosa, Miguel Ángel Molina-Vila, Rafael Rosell
Genomic analysis of circulating tumor DNA (ctDNA) released from cancer cells into the bloodstream has been proposed as a useful method to capture dynamic changes during the course of the disease. In particular, the ability to monitor epidermal growth factor receptor (EGFR) mutation status in cell-free circulating DNA (cfDNA) isolated from advanced non-small cell lung cancer (NSCLC) patients EGFR can help to the correct management of the disease and overcome the challenges associated with tumor heterogeneity and insufficient biopsied material to perform key molecular diagnosis...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826530/methylation-analyses-in-liquid-biopsy
#11
REVIEW
Delphine Lissa, Ana I Robles
Lung cancer is the leading cause of cancer-related deaths worldwide. Recent implementation of low-dose computed tomography (LDCT) screening is predicted to lead to diagnosis of lung cancer at an earlier stage, with survival benefit. However, there is still a pressing need for biomarkers that will identify individuals eligible for screening, as well as improve the diagnostic accuracy of LDCT. In addition, biomarkers for prognostic stratification of patients with early stage disease, and those that can be used as surrogates to monitor tumor evolution, will greatly improve clinical management...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826528/circulating-tumor-cells-versus-circulating-tumor-dna-in-lung-cancer-which-one-will-win
#12
REVIEW
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps
Liquid biopsies appear to be a reliable alternative to conventional biopsies that can provide both precise molecular data useful for improving the clinical management of lung cancer patients as well as a less invasive way of monitoring tumor behavior. These advances are supported by important biotechnological developments in the fields of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Analysis of CTCs and ctDNA may be useful in treatment selection, for response monitoring, and in studying resistance mechanisms...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27825420/circulating-tumor-dna-in-cancer-management
#13
Miao-Zhu Li, Ian-Zhen Lin, Hai-Tao Zhao
Molecular techniques can be very useful in detecting a patient's tumor to guide treatment decisions is increasingly been applied in the care and management of cancer patients. Circulating tumor DNA (ctDNA) containing mutations can be identified in the plasma of cancer patients during the course of the disease. As a non-invasive "liquid biopsies",ctDNA is a potential surrogate for the entire tumor genome. The use of ctDNA might help to determine the disease prognosis,monitor disease progression,monitor the molecular resistance and monitor the tumor heterogeneity...
October 10, 2016: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://www.readbyqxmd.com/read/27810330/foxl2-402c-g-mutation-can-be-identified-in-the-circulating-tumor-dna-of-patients-with-adult-granulosa-cell-tumors
#14
Anniina Färkkilä, Melissa K McConechy, Winnie Yang, Aline Talhouk, Ying Ng, Amy Lum, Ryan D Morin, Kevin Bushell, Annika Riska, Jessica N McAlpine, C Blake Gilks, Leila Unkila-Kallio, Mikko Anttonen, David G Huntsman
Adult granulosa cell tumors (AGCTs) of the ovary are molecularly characterized by the pathognomonic FOXL2 402C>G (C134W) mutation. To improve diagnostics and follow-up, we developed a specific digital droplet PCR (ddPCR) assay to detect the FOXL2 mutation in the circulating tumor DNA (ctDNA) of AGCT patients. Optimization of the ddPCR assay was performed using a TaqMan primer/probe with the RainDance RainDrop digital PCR system. The ddPCR assay was performed on circulating cell-free DNA extracted from 120 serial plasma samples collected prospectively from 35 AGCT patients...
October 31, 2016: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/27802048/endogenous-activation-induced-delivery-of-a-bioactive-photosensitizer-from-a-micellar-carrier-to-natural-dna
#15
Mohd Afzal, Saptarshi Ghosh, Sinjan Das, Nitin Chattopadhyay
The photophysics of phenosafranin (PSF), a member of the photosensitizer phenazinium family, has been explored in nonionic Triton X-165 (TX-165) micelle, calf thymus DNA (ctDNA), and a composite environment consisting of both micelle and DNA, using diverse spectroscopic techniques of both steady-state and time-resolved natures, to divulge the binding interactions of the probe with different hosts. The vivid experimental results demonstrate that PSF binds with both micelle and DNA; however, the binding affinity of the probe is much higher toward the DNA...
November 1, 2016: Journal of Physical Chemistry. B
https://www.readbyqxmd.com/read/27794262/relocation-of-a-biological-photosensitizer-from-non-ionic-micellar-carrier-to-dna-a-multispectroscopic-investigation
#16
Mohd Afzal, Saptarshi Ghosh, Nitin Chattopadhyay
Relocation of a bioactive photosensitizer, namely phenosafranin (PSF), from the phenazinium family, has been demonstrated from non-ionic micellar carrier to the DNA. For the purpose, interaction of micelle-bound PSF with calf thymus DNA (ctDNA) has been investigated vividly exploiting various spectroscopic techniques like absorption, steady state and time resolved emission, fluorescence anisotropy, circular dichroism etc. Experimental outcomes reveal that PSF binds strongly with both the micelle as well as the DNA...
October 23, 2016: Biophysical Chemistry
https://www.readbyqxmd.com/read/27791985/detection-of-circulating-tumor-dna-in-patients-with-advanced-non-small-cell-lung-cancer
#17
Yu Yao, Jinghao Liu, Lei Li, Yuan Yuan, Kejun Nan, Xin Wu, Zhenyu Zhang, Yi Wu, Xin Li, Jiaqi Zhu, Xuehong Meng, Longgang Wei, Jun Chen, Zhi Jiang
Circulating tumor DNA (ctDNA) isolated from plasma has great potential in identification of gene mutation in non-small cell lung cancers (NSCLC), which is a non-invasive technique and can avoid the inherent shortcomings of tissue biopsy. However the ability of NGS to detect gene mutation in plasma ctDNA has not been broadly explored. To assess the diagnostic ability of ctDNA for the total mutation profile, including single nucleotide variations (SNVs), insertions and deletions (indels) and gene rearrangements, we performed a targeted DNA sequencing approach to screen NSCLC related driver gene mutations in both tissue biopsies and matched blood plasma samples from 39 advanced NSCLC patients from China...
October 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27784960/circulating-tumor-dna-as-a-liquid-biopsy-target-for-detection-of-pancreatic-cancer
#18
REVIEW
Erina Takai, Shinichi Yachida
Most pancreatic cancer patients present with advanced metastatic disease, resulting in extremely poor 5-year survival, mainly because of the lack of a reliable modality for early detection and limited therapeutic options for advanced disease. Therefore, there is a need for minimally-invasive diagnostic tools for detecting pancreatic cancer at an early stage, when curative surgery and also novel therapeutic approaches including precision medicine may be feasible. The "liquid biopsy" addresses these unmet clinical needs based on the concept that simple peripheral blood sampling and detection of circulating tumor DNA (ctDNA) could provide diagnostic information...
October 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27780856/heterogeneity-of-acquired-resistance-to-anti-egfr-monoclonal-antibodies-in-patients-with-metastatic-colorectal-cancer
#19
Filippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, Alessia Mennitto, Rosa Berenato, Federica Perrone, Annunziata Gloghini, Elena Tamborini, Sara Lonardi, Federica Morano, Benedetta Picciani, Adele Busico, Chiara C Volpi, Antonia Martinetti, Francesca Battaglin, Ilaria Bossi, Alessio Pellegrinelli, Massimo Milione, Chiara Cremolini, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud
Purpose Even if RAS-BRAF wild-type and HER2/MET negative mCRC patients frequently respond to anti-EGFR monoclonal antibodies, acquired resistance almost invariably occurs. Mechanisms of resistance to EGFR blockade include the emergence of KRAS, NRAS and EGFR extracellular domain mutations as well as HER2/MET alterations. However, these findings derive from retrospective studies that analyzed one single resistance mechanism at a time; moreover, it is still unclear how molecular heterogeneity affects clonal evolution in patients...
October 25, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27772972/plasma-ctdna-for-the-detection-of-egfr-mutation-status-in-advanced-nsclc-ansclc-as-per-local-diagnostic-practices-japanese-subset-data-from-assess
#20
Takashi Yokoi, Martin Reck, Koichi Hagiwara, Baohui Han, Sergei Tjulandin, Rose McCormack, Marianne Ratcliffe, Nicola Normanno
No abstract text is available yet for this article.
February 2016: Pathology
keyword
keyword
34533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"